Williams, MC;
Hunter, A;
Shah, A;
Assi, V;
Lewis, S;
Mangion, K;
Berry, C;
Boon, NA;
Clark, E;
Flather, M;
et al.
Williams, MC; Hunter, A; Shah, A; Assi, V; Lewis, S; Mangion, K; Berry, C; Boon, NA; Clark, E; Flather, M; Forbes, J; McLean, S; Roditi, G; van Beek, EJ; Timmis, AD; Newby, DE; Scottish COmputed Tomography of the HEART (SCOT-HEART) Trial Inv
(2017)
Symptoms and quality of life in patients with suspected angina undergoing CT coronary angiography: a randomised controlled trial.
Heart, 103 (13).
pp. 995-1001.
ISSN 1468-201X
https://doi.org/10.1136/heartjnl-2016-310129
SGUL Authors: Spratt, James
|
PDF
Published Version
Available under License Creative Commons Attribution. Download (386kB) | Preview |
Abstract
BACKGROUND: In patients with suspected angina pectoris, CT coronary angiography (CTCA) clarifies the diagnosis, directs appropriate investigations and therapies, and reduces clinical events. The effect on patient symptoms is currently unknown. METHODS: In a prospective open-label parallel group multicentre randomised controlled trial, 4146 patients with suspected angina due to coronary heart disease were randomised 1:1 to receive standard care or standard care plus CTCA. Symptoms and quality of life were assessed over 6 months using the Seattle Angina Questionnaire and Short Form 12. RESULTS: Baseline scores indicated mild physical limitation (74±0.4), moderate angina stability (44±0.4), modest angina frequency (68±0.4), excellent treatment satisfaction (92±0.2) and moderate impairment of quality of life (55±0.3). Compared with standard care alone, CTCA was associated with less marked improvements in physical limitation (difference -1.74 (95% CIs, -3.34 to -0.14), p=0.0329), angina frequency (difference -1.55 (-2.85 to -0.25), p=0.0198) and quality of life (difference -3.48 (-4.95 to -2.01), p<0.0001) at 6 months. For patients undergoing CTCA, improvements in symptoms were greatest in those diagnosed with normal coronary arteries or who had their preventative therapy discontinued, and least in those with moderate non-obstructive disease or had a new prescription of preventative therapy (p<0.001 for all). CONCLUSIONS: While improving diagnosis, treatment and outcome, CTCA is associated with a small attenuation of the improvements in symptoms and quality of life due to the detection of moderate non-obstructive coronary artery disease. TRIAL REGISTRATION NUMBER: NCT01149590.
Statistics
Actions (login required)
Edit Item |